Merck KGaA

Merck KGaA’s modest stock rally follows Exane BNP Paribas’ target hike, yet investors face lingering chemicals‑sector risk, AI‑R&D uncertainty and tightening EU rules—dissecting its fundamentals and hidden upside.

Merck KGaA’s modest share rally shows investors see potential in a new AI partnership to speed drug discovery and boost long‑term growth.

Merck KGaA secures FDA Fast‑Track for cladribine capsules, a potential oral therapy that could improve muscle strength and daily living for patients with generalized myasthenia gravis.

Merck KGaA secures 16 MW of renewable power in South Korea with a 20‑year PPA to hit 80 % renewable electricity by 2030, cutting CO₂ and boosting investor confidence.

Merck KGaA is poised for growth as it advances its antibody-drug conjugate (ADC) therapy into late-stage trials, while also executing a cost-cutting strategy through the closure of its Ireland API facility, positioning the company for long-term succ…

Merck KGaA has entered into two pricing-related agreements with the US government to maintain its market share and avoid tariff exposure, while also positioning itself for future growth through investments in next-generation fertility therapies and …

Merck KGaA’s stock price surged over 10% in a single trading session, driven by a combination of regulatory developments, market trends, and the company’s own operational outlook, including revised revenue forecasts and promising late-stage clinical…

Merck KGaA, a diversified global healthcare company, is well-positioned to navigate the complex landscape of clinical microbiology, with a robust portfolio and strong financial health, despite facing operational challenges and evolving reimbursement…

Merck KGaA’s recent 2.56% share price decline is a symptom of broader market corrections, but the company’s diversified pipeline, strategic positioning in high-growth markets, and disciplined capital management position it well for long-term growth …

Merck KGaA’s stock price has experienced fluctuations over the past few weeks, influenced by market trends, while the company continues to prioritize research and development in key areas.